Overexpression of CDC25A, CDC25B or both was reported in a wide variety of human malignancies including breast, thyroid, laryngeal, esophageal, gastric, hepatocellular, ovarian, endometrial, prostate, and colorectal, non-Hodgkin lymphomas as well as in gliomas, neuroblastoma and melanoma [8] and was commonly associated with both tumor aggressiveness and poor prognosis [21]. This evidence concerns the gene CDC25A and melanoma.